Clinical Trial

Cross-linked Hyaluronic Acid/dextranomer for the Treatment of Stress Urinary Incontinence

Study acronym: (CLHA/Dx)
Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated September 26, 2024 (before its estimated March 10, 2025 completion). Its status may not reflect the trial's current state.
Summary
The investigators aimed to evaluate the effectiveness and safety of intraurethral cross-linked hyaluronic acid/dextranomer (CLHA/Dx) injection for the treatment of stress urinary incontinence (SUI) in women.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-09-18.
Trial Details
NCT Number NCT06606613
Lead Sponsor Izmir Bakircay University
Conditions Urinary Stress Incontinence (SI)
Enrollment 60 participants
Start Date 2024-10-10
Primary Completion 2025-03-10 (estimated)
Study Completion 2025-04-10 (estimated)
Updated on ClinicalTrials.gov 2024-09-26